COMPANY PROFILE

Remedium bio

Explore full profile

Adjustable, single-injection gene therapies for durable protein expression

Needham, United StatesFounded 2020Biotech & Life Sciences

Valuation $25–50M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Remedium bio

Remedium Bio is a biotechnology company developing durable protein therapeutics based on an adjustable gene therapy platform. Its proprietary Prometheus platform is designed to enable controlled, long-lasting expression of therapeutic proteins after a minimally invasive subcutaneous injection, using adipocytes (fat cells) as a durable production site, with the potential for multi-year benefit and simple post-treatment dose adjustment. The aim is to replace many frequently injected protein therapies with single-injection gene therapies at a fraction of the cost. Remedium's pipeline spans cardiometabolic and endocrine diseases as well as immunology, neurology and musculoskeletal indications. The company is led by Chief Executive Officer Frank Luppino. On 10 August 2026 Lifespan Vision Ventures announced that it is leading Remedium's $10 million Series A financing and had completed the round's initial closing, with participation from Eli Lilly and Company and HKX Capital; Harry Robb of Lifespan Vision Ventures joined the board. The financing supports advancement of its lead programmes, platform expansion and preparation for first-in-human clinical studies. Sources: PR Newswire 10 Aug 2026; remedium-bio.com.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Needham, United States
Employees: 19
Open positions: None listed
Dealroom signal: 82.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Gene Therapy, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Aug 2026	$10M	$40M	Eli Lilly · LifeSpan Vision Ventures	↗
EARLY VC✓Equity / VC	Sep 2024	$0	—	LifeSpan Vision Ventures	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Remedium bio website traffic

Latest recorded traffic for Remedium bio is 1.5K monthly website visits, down 40% over the last three months. Remedium bio's team grew 18.8% over the past year.

Latest monthly visits1.5K 3-month web change-40% 1-year team growth+18.8%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBPhageNova BioPioneering Targeted Gene Expression For Cancer and Vaccines	Summit, United States	Operational	—	$4M	—
CGCold GenesysOncolytic immunotherapy \| CG0070 \| Cold Genesys	Santa Ana, United States	Operational
GSGenenta ScienceBiotechnology company that develops gene transfer therapy for the treatment of cancer tumors	Milan, Italy	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
ATAchilles TherapeuticsAchilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells	Stevenage, United Kingdom	Closed